Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

Crizotinib is an effective drug for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), but upon treatment, the tumors inevitably become crizotinib resistant in time. The resistance mechanisms are only partly understood. In this study, we aim to identify gene...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancers (Basel)
Päätekijät: Wei, Jiacong, van der Wekken, Anthonie J., Saber, Ali, Terpstra, Miente M., Schuuring, Ed, Timens, Wim, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke, Kok, Klaas
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5789360/
https://ncbi.nlm.nih.gov/pubmed/29300322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10010010
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia